Search

everythinglearnresearchcommunity

for

Search:↓

Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.

Finasteride is effective for male hair loss, teledermatology is accurate and accepted, and cyclosporin helps treat toxic epidermal necrolysis.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Rituximab can cause skin issues, but baricitinib may help improve them.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Rituximab may cause skin issues, but baricitinib can help improve them.

Bexxar treatment led to a high response rate in patients with advanced-stage, treatment-resistant follicular lymphoma.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Budesonide alone is less effective than standard treatment for autoimmune hepatitis.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Baricitinib helped treat a man's beard hair loss when steroids didn't work.

An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Ocrelizumab may cause pancreatitis in some patients.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

New treatments for lupus show promise, but more research is needed, especially for children.